Evidence map›Paper›PMID 24008128›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2013

Colorectal adenoma stem-like cell populations: associations with adenoma characteristics and metachronous colorectal neoplasia.

Angela N Bartley, Nila Parikh, Chiu-Hsieh Hsu, Denise J Roe, Julie A Buckmeier, Lynda Corley, Ron A Phipps, Gary Gallick, Peter Lance, Patricia A Thompson and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Milestones of Lynch syndrome: 1895-2015.Nature reviews. Cancer · 2015
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Angela N BartleyUniversity of Arizona Cancer Center, 1515 Campbell Avenue, Tucson, AZ 85724. PThompson@azcc.arizona.edu.
Nila Parikh
Chiu-Hsieh Hsu
Denise J Roe
Julie A Buckmeier
Lynda Corley
Ron A Phipps
Gary Gallick
Peter Lance
Patricia A Thompson
Stanley R Hamilton
The University of Texas MD Anderson Cancer Center · USUniversity of Arizona · USUniversity of Arizona Cancer Center

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
WHEAT BRAN FIBER SUPPLEMENTS ON THE RECURRENCE OF COLONIC ADENOMASP01CA041108 · NCI · UNIVERSITY OF ARIZONA · PI HAMILTON, STANLEY R. · 1986 to 2009
$38.8M
Selenium Colorectal Cancer Chemoprevention TrialsR01CA151708 · NCI · UNIVERSITY OF ARIZONA · PI JACOBS, ELIZABETH T · 2011 to 2021
$6.8M
NCI NIH HHS P01 CA041108NCI NIH HHS P01 CA41108NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA151708
6 · The paper itself

Abstract

Cancer stem cells have tumor-initiation and tumor-maintenance capabilities. Stem-like cells are present in colorectal adenomas, but their relationship to adenoma pathology and patient characteristics, including metachronous development of an additional adenoma ("recurrence"), has not been studied extensively. We evaluated the expression of aldehyde dehydrogenase isoform 1A1 (ALDH1A1), a putative stem cell marker, in baseline adenomas from the placebo arm of chemoprevention trial participants with colonoscopic follow-up. An exploratory set of 20 baseline adenomas was analyzed by ALDH1A1 immunohistochemistry with morphometry, and a replication set of 89 adenomas from 76 high-risk participants was evaluated by computerized image analysis. ALDH1A1-labeling indices (ALI) were similar across patient characteristics and in advanced and nonadvanced adenomas. There was a trend toward higher ALIs in adenomas occurring in the right than left colon (P = 0.09). ALIs of synchronous adenomas were correlated (intraclass correlation coefficient 0.67). Participants in both sample sets who developed a metachronous adenoma had significantly higher ALIs in their baseline adenoma than participants who remained adenoma free. In the replication set, the adjusted odds for metachronous adenoma increased 1.46 for each 10% increase in ALIs (P = 0.03). A best-fit algorithm-based cutoff point of 22.4% had specificity of 75.0% and positive predictive value of 70.0% for metachronous adenoma development. A larger population of ALDH1A1-expressing cells in an adenoma is associated with a higher risk for metachronous adenoma, independent of adenoma size or histopathology. If confirmed, ALDH1A1 has potential as a novel biomarker in risk assessment and as a potential stem cell target for chemoprevention.

Indexed as

AdenomaAgedAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyBiomarkers, TumorColonoscopyColorectal NeoplasmsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasms, Second PrimaryNeoplastic Stem CellsPrognosisAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorRetinal Dehydrogenase

Identifiers

PMID24008128
PMCPMC4079278
OpenAlexW2096006040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.